Stockscreener 앱 받기
28.87
2.56%
0.72
시장 영업 전:
28.90
0.03
+0.10%
전일 마감가:
$28.15
열려 있는:
$28.41
하루 거래량:
989.03K
Relative Volume:
0.36
시가총액:
$3.60B
수익:
$22.12M
순이익/손실:
$-245.15M
주가수익비율:
-7.4898
EPS:
-3.8546
순현금흐름:
$-373.40M
1주 성능:
-1.77%
1개월 성능:
+9.56%
6개월 성능:
+527.61%
1년 성능:
+528.98%
1일 변동 폭
$28.19
$29.39
1주일 범위
$27.73
$30.06
52주 변동 폭
$2.7601
$30.60
Alumis Inc Stock (ALMS) Company Profile
명칭
Alumis Inc
전화
650-231-6625
주소
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
28.87 | 3.51B | 22.12M | -245.15M | -373.40M | -3.8546 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-21 | 개시 | Chardan Capital Markets | Buy |
| 2025-07-25 | 개시 | Wells Fargo | Overweight |
| 2025-06-10 | 재개 | Guggenheim | Buy |
| 2025-01-30 | 개시 | Oppenheimer | Outperform |
| 2024-10-31 | 개시 | Robert W. Baird | Outperform |
| 2024-10-17 | 개시 | H.C. Wainwright | Buy |
| 2024-07-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-23 | 개시 | Guggenheim | Buy |
| 2024-07-23 | 개시 | Leerink Partners | Outperform |
| 2024-07-23 | 개시 | Morgan Stanley | Overweight |
모두보기
Alumis Inc 주식(ALMS)의 최신 뉴스
Phase III wins lift Alumis, Corcept shares in January - bioworld.com
Alumis to Present at the Leerink Partners Global Healthcare Conference - The Manila Times
ALMS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ALMS Stock Price, Quote & Chart | ALUMIS INC (NASDAQ:ALMS) - ChartMill
Alumis Inc. (NASDAQ:ALMS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference - Yahoo Finance
ALMS SEC FilingsAlumis Inc 10-K, 10-Q, 8-K Forms - Stock Titan
This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Alumis Inc. (ALMS) Investor Outlook: Analyzing a Potential 29% Upside in Biotech Innovation - DirectorsTalk Interviews
Aug Retail: Is Alumis Inc gaining market sharePortfolio Return Summary & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
ALMS Should I Buy - Intellectia AI
This Oracle Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Stifel Nicolaus Initiates Coverage on Alumis (NASDAQ:ALMS) - MarketBeat
Stifel Initiates Alumis at Buy With $44 Price Target - marketscreener.com
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Stifel initiates Alumis stock with buy rating on TYK2 potential - Investing.com Australia
Stifel initiates Alumis stock with buy rating on TYK2 potential By Investing.com - Investing.com Canada
ALMS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Alumis Inc. (ALMS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
A | What is Alumis Inc.'s debt-to-equity ratio2025 Macro Impact & Fast Moving Trade Plans - mfd.ru
Big Picture: Is Alumis Inc in a consolidation phaseWeekly Trend Report & Long-Term Growth Plans - baoquankhu1.vn
Alumis Inc stock hits all-time high at 28.34 USD By Investing.com - Investing.com India
Alumis Inc stock hits all-time high at 28.34 USD - Investing.com Nigeria
Alumis (NASDAQ:ALMS) Sets New 52-Week HighStill a Buy? - MarketBeat
Risk Hedge: Is Alumis Inc gaining market shareJuly 2025 Retail & Technical Pattern Based Buy Signals - baoquankhu1.vn
Huge insider buying now at this insurance giant and 2 biotechs - MSN
Alumis Stock: Key Catalysts on the Horizon for 2026 - AD HOC NEWS
Credit Industriel ET Commercial Sells 140,000 Shares of Alumis Inc. $ALMS - MarketBeat
Why Alumis Inc. stock is trending among retail tradersProduct Launch & Weekly Watchlist for Hot Stocks - mfd.ru
Can Alumis Inc. expand into new markets2025 Momentum Check & Short-Term Swing Trade Alerts - mfd.ru
Alumis (NASDAQ:ALMS) Shares Up 7.2%Still a Buy? - MarketBeat
Alumis Highlights Phase III Psoriasis Wins, NDA Timing, and Lupus Catalyst at Guggenheim Summit - MarketBeat
Alumis Inc. (ALMS) Investor Outlook: Biotech Innovator With A 45% Upside Potential - DirectorsTalk Interviews
Is Alumis Inc.’s growth already priced inPortfolio Growth Summary & Weekly Watchlist of Top Performers - mfd.ru
Quarterly Risk: Is Alumis Inc in a consolidation phase2025 Price Action Summary & Growth Focused Entry Reports - baoquankhu1.vn
Can Alumis Inc. ride the EV wave2025 Pullback Review & Weekly High Potential Stock Alerts - mfd.ru
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. - AOL.com
Alumis (ALMS) Valuation Check After Strong Multi‑Month Share Price Momentum - Yahoo Finance
Alumis Ownership Shifts As Shelf Filing And Conferences Shape Outlook - Sahm
EPS Watch: Can Alumis Inc ride the EV waveWeekly Stock Analysis & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Market Leaders: Will TWFG outperform the market in YEARTrade Analysis Report & High Win Rate Trade Alerts - baoquankhu1.vn
Alumis to Participate in Upcoming February Investor Conferences - The Manila Times
Biotech firm Alumis lines up two February investor webcasts - Stock Titan
Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Alumis and ACELYRIN announce merger in all-stock deal - MSN
Alumis (NASDAQ:ALMS) Stock Price Up 9.8%What's Next? - MarketBeat
Alumis Inc stock (ALMS) jumps again on Nasdaq — here’s what’s driving the move and what comes next - TechStock²
Why Alumis Inc. Stock Is Suddenly Powering Higher - TipRanks
Chardan highlights Alumis’s (ALMS) potential after envudeucitinib hits all phase 3 endpoints in psoriasis trials - MSN
Top Small Cap Stocks To Watch NowJanuary 6th - MarketBeat
Chardan Highlights Alumis's (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials - Finviz
Alumis Inc (ALMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):